LP Building Solutions (LP; NYSE: LPX), a leading manufacturer of high-performance building products, will report its third quarter 2026 financial results on Tuesday, Nov. 3, 2026.

The easiest way to install Windows 11 26H2 Update is to use the Windows 11 Settings app. Open Windows 11 Settings and go to Windows Update. Now, click Check for Updates. However, if Windows 11 25H2 ...

LP Building Solutions, a leading manufacturer of high-performance building products, announced Sept. 29 a new distribution ...

BlueLinx Holdings Inc. a annoncé l’élargissement de son partenariat avec LP Building Solutions, qui étend l’offre LP® SmartSide® Trim & Siding de la société sur des marchés clés ...

BlueLinx Holdings Inc. (NYSE: BXC), a leading U.S. wholesale distributor of building products, today announced an expanded partnership with LP Building Solutions that broadens the company's LP® ...

Louisiana-Pacific Corporation (NYSE:LPX) is an unusual housing stock. Its results still move with the construction cycle, but ...

With the ongoing challenges to developing housing at an affordable cost, every input matters. Here are some of the latest and greatest programs.

Avant de s’installer dans le fauteuil de procureur de la République de Bobigny (Seine-Saint-Denis), depuis 1er septembre, Alexandre de Bosschère, 53 ans, s’était attelé au vaste chantier du numérique ...

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

LP Building Solutions, a manufacturer of high-performance building products, expanded its LP SmartSide Trim & Siding portfolio with the introduction of the new LP SmartSide Primed 8” Brushed Smooth ...

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.